Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.32 |
| ▸ | GAA | P10253 | 2/20 | 0.32 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | ALPL | P05186 | 1/20 | 0.31 |
| ▸ | IDO1 | P14902 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | TTK | P33981 | 1/20 | 0.31 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.31 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.30 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29876415 | 0.77 | HTR2C (0.39) | CYP1A2KDM4EGAAPDPK1CYP3A4 | |
| SCHEMBL311147 | 0.66 | MAPK1 (0.52) | KDM4EGAAPDPK1CYP3A4ALDH1A1 | |
| SCHEMBL10535470 | 0.60 | KMT2A (0.63) | KDM4EALDH1A1HPGDNPC1TP53 | |
| SCHEMBL3067812 | 0.59 | HPGD (0.55) | KDM4EGAAPDPK1CYP3A4ALDH1A1 | |
| SCHEMBL18228562 | 0.59 | HPGD (0.55) | KDM4EGAAPDPK1CYP3A4ALDH1A1 | |
| SCHEMBL23536581 | 0.59 | LRRK2 (0.56) | KDM4EGAAALDH1A1HPGDMAPK10 | |
| SCHEMBL31190616 | 0.59 | KDM4E (0.43) | CYP1A2KDM4EGAAPDPK1CYP3A4 | |
| SCHEMBL23536566 | 0.59 | KDM4E (0.40) | CYP1A2KDM4EGAAPDPK1CYP3A4 | |
| SCHEMBL381385 | 0.59 | KDM4E (0.50) | CYP1A2KDM4EGAAPDPK1CYP3A4 | |
| SCHEMBL4053256 | 0.58 | HPGD (0.58) | KDM4EGAAPDPK1CYP3A4ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11299492-B2 | JAK kinase inhibitor compounds for treatment of respiratory disease | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2022-04-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11299492-B2 | JAK kinase inhibitor compounds for treatment of respiratory disease | JAK1, JAK2, JAK3 | CYP1A2 1571/4885KDM4E 638/4885GAA 1348/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.